The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a ...

Starting Sept. 1, the U.S. will impose a “Most Favored Nation” (MFN) tariff rate on generic pharmaceuticals sourced from the EU, including their ingredients and chemical precursors, according to a ...

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). | For the second time ...

Johnson & Johnson will spend $2 billion over the next 10 years to operate a 160,000-square-foot manufacturing facility at Fujifilm Diosynth’s massive biomanufacturing campus in Holly Springs, North ...

Leo reported that sales of eczema treatment Adbry are scaling up in the U.S. The company also made a positive adjustment to its 2025 sales guidance.

Swoop and iSpot have joined forces to deliver insights into cross-platform ad exposures against specific audiences for healthcare and pharma marketers. | Swoop and iSpot have joined forces to deliver ...

As its lead candidate advances into a late-stage trial, Inhibikase has picked up a commercial leader with plenty of experience in the PAH space.

Nucleus RadioPharma, a CDMO that specializes in the burgeoning field of radiopharmaceuticals, named former FDA Commissioner Dr. Stephen Hahn as its chief executive officer.

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate ...